Results 241 to 250 of about 165,965 (304)

GLP-1 Receptor Agonists

RCSB Protein Data Bank
ABSTRACT Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in primary care for diabetes, obesity, and other conditions, offering glycemic control, weight loss, and cardioprotection. This article explores the indications, benefits, risks, and prescribing considerations of GLP-1RAs for nurse practitioners (NPs ...
Clifford J. Rosen, Julie R. Ingelfinger
  +8 more sources

GLP-1 receptor agonists in NAFLD

Diabetes & Metabolism, 2017
Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (
Petit, Jean-Michel, Vergès, Bruno
openaire   +2 more sources

Emerging GLP-1 receptor agonists

Expert Opinion on Emerging Drugs, 2011
Recently, glucagon-like peptide-1 receptor (GLP-1R) agonists have become available for the treatment of type 2 diabetes. These agents exploit the physiological effects of GLP-1, which is able to address several of the pathophysiological features of type 2 diabetes.
Lund, Asger, Knop, Filip K, Vilsbøll, Tina   +2 more
openaire   +3 more sources

GLP-1 receptor agonists today

Diabetes Research and Clinical Practice, 2011
Type 2 diabetes mellitus (T2DM) is a complex, progressive disease affecting an estimated 257 million people worldwide. A number of unmet needs exist with traditional T2DM therapies, which can lead to insufficient glycaemic control and increased risk of diabetes-associated complications.
Michel, Marre, Alfred, Penfornis
openaire   +2 more sources

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials.

Diabetes Care
OBJECTIVE To provide an updated synthesis on effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on weight, BMI, and waist circumference incorporating newer randomized controlled trials (RCTs), particularly in individuals with overweight or ...
Hon Jen Wong, Bryan Sim, Y. Teo, Y. Teo, M. Chan, L. Yeo, P. Eng, B. Tan, N. Sattar, M. Dalakoti, Ching-Hui Sia   +10 more
semanticscholar   +1 more source

Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study

Obesity Pillars
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) drug-induced weight loss is associated with fat mass reduction but can also lead to nutritional deficiencies and loss of muscle.
W. Scott Butsch, S. Sulo, Andrew T. Chang, Jeeyun Kim, Kirk W. Kerr, Dominique R. Williams, R. Hegazi, Thadchaigeni Panchalingam, Scott Goates, S. Heymsfield   +9 more
semanticscholar   +1 more source

Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists

JAMA Surgery
Key Points Question How do bariatric surgery and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compare as obesity treatments regarding weight loss, ongoing costs, and health care utilization in a clinical setting? Findings This cohort study of 30 
Tyson S. Barrett, Juliane O. Hafermann, Shannon Richards, Keith LeJeune, George M. Eid   +4 more
semanticscholar   +1 more source

GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity

JAMA Oncology
IMPORTANCE Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely prescribed for glycemic control in type 2 diabetes and have recently gained popularity for weight management.
Hao Dai, Yongqiu Li, Y. Lee, Ying Lu, Thomas J. George, W. Donahoo, Kelvin P Lee, H. Nakshatri, John M Allen, Yi Guo, Ramon C Sun, Jingchuan Guo, Jiang Bian   +12 more
semanticscholar   +1 more source

Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,592 patients.

Journal of the American College of Cardiology
BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits particularly in patients with diabetes mellitus (DM), but the safety and efficacy of different GLP-1 RAs across diverse ...
M. Galli, S. Benenati, C. Laudani, Beatrice Simeone, G. Sarto, L. Ortega‐Paz, Erica Rocco, Marco Bernardi, L. Spadafora, Domenico D'Amario, Ernesto Greco, Giacomo Frati, Massimo Federici, R. Mehran, Filippo Crea, D. Angiolillo, S. Sciarretta   +16 more
semanticscholar   +1 more source